Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Amgen    AMGN

AMGEN (AMGN)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 Analysis summary4-Traders Strategies

Anaïs Lozach

Analyst
 
share with twitter share with LinkedIn share with facebook
share via e-mail

Back on key levels based on weekly price data

Strategy published on 11/10/2017 | 08:31
long trade
Live
Entry price : 173.15$ | Target : 192$ | Stop-loss : 164.9$ | Potential : 10.89%
Amgen shares are closing near attractive entry levels for a medium term horizon. Investors could regard the decline over the past weeks as a buying opportunity.
Investors have an opportunity to buy the stock and target the $ 192.
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
Strengths
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Historically, the company has been releasing figures that are above expectations.
Weaknesses
  • According to Thomson-Reuters' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
AMGEN19.97%128 762
JOHNSON & JOHNSON21.53%383 877
NOVARTIS12.01%221 304
PFIZER10.04%218 400
ROCHE HOLDING LTD.3.40%210 833
MERCK AND COMPANY-6.96%155 214
SANOFI-4.32%111 499
NOVO NORDISK A/S29.49%105 152
BAYER5.62%104 029
BRISTOL-MYERS SQUIBB COMPAN..6.81%103 881
ELI LILLY AND COMPANY17.54%96 775
ABBOTT LABORATORIES42.38%95 837
GLAXOSMITHKLINE-17.57%86 798
CELGENE CORPORATION-8.35%85 188
ASTRAZENECA9.90%83 019
ALLERGAN PLC-20.10%56 286
More Results
Financials ($)
Sales 2017 22 886 M
EBIT 2017 11 755 M
Net income 2017 8 326 M
Finance 2017 6 819 M
Yield 2017 2,54%
P/E ratio 2017 15,76
P/E ratio 2018 15,70
EV / Sales 2017 5,33x
EV / Sales 2018 5,14x
Capitalization 129 B
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes
Chart AMGEN
Duration : Period : Day
Amgen Technical Analysis Chart | AMGN | US0311621009 | 4-Traders
Duration : Period : Week
Amgen Technical Analysis Chart | AMGN | US0311621009 | 4-Traders